Because of the crosstalk between the JAK/STAT3 signaling pathway and many other oncogenic pathways (e.g., NF-κB, PI3K, and BCL2) in B- and T-cell lymphoma [65,121], combination therapy that targets JAK/STAT3 and additional oncogenic signaling pathways may increase the effectiveness of treatments. The gene discussed is STAT3; the disease is T-cell non-Hodgkin lymphoma.